Updated April 2026 · CMS & FDA public data
Drug Pricing Guides
Long-form, data-driven guides to U.S. prescription drug pricing — how the supply chain actually works, why a single drug can carry five different prices, and how to pay less at the pharmacy counter. Every guide is built from public CMS NADAC, FDA Orange Book, and HHS data, with no manufacturer or PBM sponsorship.
Why Drug Pricing Is So Confusing
U.S. prescription drug pricing is layered. Manufacturers publish a wholesale acquisition cost (WAC). Wholesalers sell to pharmacies at NADAC, the National Average Drug Acquisition Cost tracked monthly by CMS. Insurers and pharmacy benefit managers (PBMs) negotiate confidential rebates that lower the net price they pay but are mostly invisible to patients. The cash price at the counter is something else again, and the price after a copay card or discount program is a fourth number. The same drug can carry a $700 list price, a $250 net price after rebates, and a $19 Cost Plus Drugs price for the same prescription on the same day.
These guides work through each layer one at a time, with worked examples and links back to the source datasets. The goal is not generic financial advice — it is a clear map of where the dollars go so you can recognize which strategy applies to a specific prescription.
Browse Guides by Topic
Saving Money
Reference content on a specific corner of U.S. prescription drug pricing, written from public CMS, FDA, and HHS data sources with no manufacturer or PBM sponsorship.
How It Works
How U.S. drug pricing actually works under the hood — the WAC list price, AWP, NADAC, the PBM rebate flow, the 340B program, and why a drug can have five different prices for five different patients.
Drug Types
Therapeutic-class deep dives that compare drugs head-to-head — every statin, every GLP-1, every PPI — using public CMS Medicare Part D spending data to surface the cheapest clinically equivalent option.
How These Guides Are Researched
Every drug-pricing claim in these guides traces back to a public federal dataset. Spending and per-claim averages come from the CMS Medicare Part D Drug Spending Dashboard. Acquisition cost benchmarks come from CMS NADAC. Patent expiration, exclusivity, and generic approval timelines come from the FDA Orange Book. Drug labeling and manufacturer relationships come from openFDA. Every guide ends with the source list and a refresh date so the data is auditable. Read the full DrugPrice methodology for how the score, rankings, and class comparisons are computed.
DrugPrice is not medical advice. Guides describe what the public pricing data shows; they do not recommend a specific treatment, switch a generic for a brand, or substitute for a conversation with your prescriber and pharmacist. If a guide flags a cheaper clinically equivalent option, treat that as a starting point for that conversation, not a clinical recommendation.
Frequently Asked Questions
Why do U.S. drug prices vary so much?
A single drug routinely has five different prices: the manufacturer's wholesale list price (WAC), the average wholesale price (AWP) used in older contracts, the National Average Drug Acquisition Cost (NADAC) that pharmacies actually pay, the Medicare-negotiated price for selected drugs, and the cash price you see at the counter. Pharmacy benefit managers, manufacturer rebates, and 340B discounts all sit between those numbers. The DrugPrice guides walk through each layer using public CMS Medicare Part D and FDA Orange Book data.
What is the cheapest way to fill a prescription in 2026?
There is no single cheapest channel — the right answer depends on the drug. For most generic maintenance medications, Mark Cuban Cost Plus Drugs and Amazon Pharmacy are typically lowest. For brand-name drugs with manufacturer copay cards, the manufacturer program usually beats discount cards. For seniors on Medicare, the new $2,000 annual out-of-pocket cap (effective January 2025) reshaped which strategies pay off. The "Cheapest Drugs by Class" guide compares actual NADAC pricing across every major therapeutic category.
How does Medicare drug price negotiation work?
Under the Inflation Reduction Act, the Centers for Medicare & Medicaid Services negotiates prices directly with manufacturers for a rotating list of high-spend Part D drugs. The first ten negotiated prices took effect January 2026, with discounts of 38–79% off list price. CMS publishes the official maximum fair prices on its negotiation page; the DrugPrice Medicare guide tracks each round, the drugs included, and timing of patient impact.
Are generics and biosimilars really equivalent to brand drugs?
For small-molecule generics, yes — the FDA requires generics to demonstrate the same active ingredient, strength, dosage form, route, and bioequivalence (within 80–125% of brand pharmacokinetics) to receive an A-rated approval. Biosimilars are highly similar — not identical — to a reference biologic, with no clinically meaningful differences in safety, purity, or potency. The biosimilars guide explains the distinction and lists every approved Humira, Stelara, and Avastin biosimilar and its launch date.
Where does DrugPrice get its numbers?
Spending and average cost-per-claim data comes from the CMS Medicare Part D Drug Spending Dashboard. Patent and generic launch dates come from the FDA Orange Book. Manufacturer ownership and approval status come from the FDA Drugs@FDA database. Negotiated Medicare prices come directly from CMS's negotiation announcements. We do not estimate or model — every number on every page is drawn from a public federal dataset and labeled with its source. Last refreshed April 2026.
Sources: CMS Medicare Part D Drug Spending Dashboard, CMS NADAC, FDA Orange Book, openFDA, HHS Office of the Inspector General. All data is U.S. government public domain. Cite as: "DrugPrice, April 2026 reading. Data: CMS Part D & FDA."
Last updated 2026-04-06 · 3 guides published.